Emergent BioSolutions | EBS - 贸易债权人



金融业
股票价格
USD
资产
USD 1.82B
现金及等价物
USD 111.7M
销售成本
USD 381.2M
流动资产
USD 679.5M
流动负债
USD 651.3M
债务
USD 903.2M
股息收益率
0
EBIT
USD -148.1M
EBITDA
USD -113.5M
员工
1.6K
EPS每股收益
USD -0.77
股本和储备
USD 649.3M
销售毛利
USD 10M
债务利息支出
USD 17.9M
贷款资金
USD 446.5M
市值
USD 479.2M
净收入
USD -261.3M
营业费用
USD 555.9M
营业利润
USD -218M
普通股股本
USD 100K
PE价格收益
14.4
税前利润
USD -130.8M
销售收入
USD 276.6M
销售和管理费用
USD 182.8M
股票
USD 328.9M
贸易债权人
USD 112.2M
应收帐款人
USD 290.1M


贸易债权人 更改 日
Acadia Pharmaceuticals USD 12.25M 1.34M 2026-03
Akebia Therapeutics USD 8.39M 12.8M 2026-03
ALKERMES USD 102.36M 5.59M 2026-03
Alnylam Pharmaceuticals USD 126.63M 10.91M 2026-03
Amarin USD 48.15M 2.8M 2026-03
ANI Pharmaceuticals USD 69.69M 7.11M 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Coherus Biosciences USD 9.91M 14.98M 2025-12
Emergent BioSolutions USD 112.2M 500K 2023-12
Exelixis USD 24.15M 5.47M 2026-03
Glaxosmithkline GBP 20.72B 346.14M 2025-12
Heron Therapeutics USD 8.97M 24K 2026-03
Ionis Pharmaceuticals USD 26.03M 2.05M 2026-03
Ironwood Pharmaceuticals USD 3.24M 339K 2026-03
Lexicon Pharmaceuticals USD 3M 87K 2026-03
Lonza CHF 471M 3M 2024-12
Merck USD 3.86B 541M 2026-03
Moderna USD 161M 156M 2026-03
Myriad Genetics USD 32.6M 2.6M 2026-03
Nektar Therapeutics USD 10.77M 4.79M 2025-12
Neurocrine Biosciences USD 691.3M 145.8M 2026-03
Pacira USD 14.01M 1.14M 2026-03
Pfizer USD 4.51B 734M 2026-03
PTC Therapeutics USD 25.48M 20M 2026-03
Sanofi EUR 22.71B 219M 2026-03
Sarepta Therapeutics USD 70.38M 210.46M 2026-03
United Therapeutics USD 498.3M 491.2M 2026-03
Vanda Pharmaceuticals USD 39.09M 33.28M 2024-12
Xoma USD 2.65M 1.52M 2025-09